Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder
Key facts
- Who runs it
- National Institute on Drug Abuse (NIDA)
- Where
- Charlottesville, Dallas, Indianapolis, Kansas City, Little Rock, Los Angeles, Memphis, Minneapolis, Pickens, Portland, and San Diego, United StatesSee the 11 sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 3
- People taking part
- 360 people, planned
- Started
- 1 Jul 2024
- Expected to end
- 30 Apr 2027
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- extended-release naltrexone (XR-NTX)
- extended release bupropion (BUP-XL) tablets (BUP-XL)
- iPLB
- oPLB
- Record updated
- 13 July 2026
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 29 criteriaShow less
Who can take part
- Is 18 to 65 years of age
- Meets DSM-5 criteria for moderate or severe MUD (4 or more criteria)
- Is interested in reducing or stopping MA use
- Is able to speak English sufficiently to understand the study procedures and provide written informed consent to participate in the study
- Self-reports MA use on 18 or more days in the 30-day period prior to consent using the Timeline Followback (TLFB)
- Provides at least 2 urine samples positive for MA out of up to 3 tests, which will occur at least 2 days apart within a 10-day period
- If assigned as female at birth and/or currently has a uterus, is not pregnant, agrees to use acceptable birth control methods, and have periodic urine pregnancy testing done during participation in the study unless documentation of hysterectomy provided
- Is not physically dependent on opioids and meets subjective and objective measures of being opioid-free prior to naltrexone injection per study medical clinician's determination, including, if clinically required, a negative naloxone challenge
- Is willing to comply with all study procedures and medication instructions
- Agrees to use a smartphone app (downloaded for free to own device or on a study provided smartphone device) to take daily videos of medication dosing
Who cannot take part
- Has been in a prior study of pharmacological or behavioral treatment for MUD within 6 months of study consent
- Has taken an investigational drug in another study within 30 days of study consent
- Is receiving ongoing treatment with tricyclic antidepressants, xanthines (i.e., theophylline and aminophylline), systemic corticosteroids, nelfinavir, efavirenz, chlorpromazine, MAOIs, central nervous system stimulants (e.g., Adderall, Ritalin, etc.), or any medication that, in the judgment of the study medical clinician, could interact adversely with study medications
- Requires treatment with opioid-containing medications (e.g., opioid analgesics) during the study period
- Has a surgery planned or scheduled during the study period
- Has an acute medical or psychiatric disorder that would, in the judgment of the study medical clinician, make participation difficult or unsafe
- Has a history of epilepsy, seizure disorder, or head trauma with neurological sequelae (e.g., loss of consciousness that required hospitalization); current anorexia nervosa or bulimia; or any other conditions that increase seizure risk in the opinion of the study medical clinician
- Has Stage 2 hypertension as determined by the study medical clinician (e.g., greater than or equal to 160/100 in 2 out of 3 readings during screening)
- Has a known allergy or sensitivity to bupropion, naloxone, naltrexone, PLG (polyactideco-glycolide), carboxymethylcellulose or any other component of the XR-NTX diluents
- Is concurrently enrolled in formal behavioral or pharmacological Substance Use Disorder (SUD) treatment services
- Has evidence of second or third degree heart block, atrial fibrillation, atrial flutter, prolongation of the QTc, or any other finding on the screening ECG that, in the opinion of the study medical clinician, would preclude safe participation in the study
- Has any elevated bilirubin test value per laboratory criteria OR any other liver function test (LFT) value > 5 times the upper limit of normal per laboratory criteria
- Has a platelet count <100 x 10exp3/microliter
- Has suicidal or homicidal ideation that requires immediate attention
- Has a body habitus that precludes gluteal intramuscular injection of XR-NTX in accordance with the administration equipment (needle) and procedures
- Has been prescribed and taken naltrexone or bupropion within 30 days of study consent
- Has a current pattern of alcohol, benzodiazepine, or other sedative hypnotic use which would preclude safe participation in the study as determined by the study medical clinician
- Is currently in jail, prison or any inpatient overnight facility as required by court of law or have pending legal action or other situation (e.g., unstable living arrangements) that could prevent participation in the study or in any study activities
- If assigned as female at birth and/or currently has a uterus, is currently pregnant, breastfeeding, or planning on conception
Where in United States
- University of VirginiaCharlottesville, United States
- University of Texas Southwestern Medical CenterDallas, United States
- Indiana UniversityIndianapolis, United States
- University of Kansas Medical CenterKansas City, United States
- University of Arkansas for Medical SciencesLittle Rock, United States
- University of California, Los AngelesLos Angeles, United States
- University of TennesseeMemphis, United States
- University of MinnesotaMinneapolis, United States
- MUSC/BHSPickens, United States
- CODAPortland, United States
- University of California At San DiegoSan Diego, United States
About the trial
What the trial wants to find out
The primary objective of this study is to evaluate the efficacy of extended release naltrexone plus bupropion XL (XR-NTX/BUP-XL) compared to matched injectable and oral placebo (iPLB/oPLB) in reducing methamphetamine (MA) use in individuals with moderate or severe methamphetamine use disorder (MUD) seeking to stop or reduce MA use.
The 2 groups in the trial
- XR-NTX/BUP-XLTreatment being tested
Participants randomized to the (XR-NTX/BUP-XL) arm will receive 450 mg of once-daily oral extended-release bupropion tablets and once every three weeks (Weeks 1, 4, 7, and 10) injections of extended-release naltrexone (Vivitrol®)
Treatment: extended-release naltrexone (XR-NTX) and extended release bupropion (BUP-XL) tablets (BUP-XL)
- PLB/PLBPlacebo, for comparison
Participants randomized to the PLB arm will receive once-daily placebo tablets and once every three weeks (Weeks 1, 4, 7, and 10) placebo injections.
Treatment: iPLB and oPLB
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Randomized, Placebo-Controlled, Multi-Site Trial of Extended-Release Naltrexone Injection/Bupropion XL Tablets in the Treatment of Methamphetamine Use Disorder
- Record updated
- 13 July 2026